Health

Boehringer Ingelheim, Phase III study on Survodutide shows a targeted reduction of visceral and liver fat

ROMA (ITALPRESS) – Boehringer Ingelheim today announced positive results from two global Phase III studies on its dual glucagon/ agonist GLP-1 survodutide (BI 456906): Synchronize-1 and Synchronize-Masld. The results show the potential of survodutide in promoting weight loss and, consequently,

Boehringer Ingelheim, Phase III study on Survodutide shows a targeted reduction of visceral and liver fat Read More »

Scroll to Top